Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Genetic Technologies Limited GENE
$0.94
-$0.03 (-2.92%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
23232432.00000000
-
week52high
2.40
-
week52low
0.83
-
Revenue
6794816
-
P/E TTM
0
-
Beta
0.53167900
-
EPS
-0.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 авг 2022 г. в 04:00
Описание компании
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Sell | Buy | 25 ноя 2020 г. |
| Ladenburg Thalmann | Sell | Buy | 16 ноя 2012 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Genetic Technologies Limited (GENE) Q3 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 23:45
Genetic Technologies Limited (NASDAQ:GENE ) Q3 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Tony Di Pietro - Chief Financial Officer Conference Call Participants Adrian Mulcahy [Abrupt Start] FY 2023. I'm really pleased to have both Simon Morriss, the CEO; and Tony Di Pietro.
Best Penny Stocks To Buy: 5 To Watch With Big News This Week
PennyStocks
06 февр 2023 г. в 10:19
Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy: 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy: 4 To Watch With Big News In February
PennyStocks
03 февр 2023 г. в 09:31
Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Genetic Technologies (GENE) Stock Up 173% Today?
InvestorPlace
03 февр 2023 г. в 08:35
Genetic Technologies (NASDAQ: GENE ) stock is taking off on Friday as the company prepares for new cancer tests areas. The big news here is Genetic Technologies signing an agreement with QIAGEN, a global leader in molecular testing.
Genetic Technologies Limited (GENE) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 ноя 2022 г. в 06:59
Genetic Technologies Limited (NASDAQ:GENE ) Q1 2023 Earnings Conference Call November 3, 2022 8:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Adrian Mulcahy [Starts Abruptly] Genetic Technologies First Quarter FY '23 Investor Webinar. We have with us today, which is great news, is Simon Morriss, the CEO of Genetic Technologies.